DK3250563T3 - Substituerede triazoler og fremgangsmåder, der vedrører disse - Google Patents
Substituerede triazoler og fremgangsmåder, der vedrører disse Download PDFInfo
- Publication number
- DK3250563T3 DK3250563T3 DK16703250.7T DK16703250T DK3250563T3 DK 3250563 T3 DK3250563 T3 DK 3250563T3 DK 16703250 T DK16703250 T DK 16703250T DK 3250563 T3 DK3250563 T3 DK 3250563T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods related
- substituted triazoles
- triazoles
- substituted
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110415P | 2015-01-30 | 2015-01-30 | |
| US201562259314P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/015740 WO2016123533A1 (fr) | 2015-01-30 | 2016-01-29 | Triazoles substitués et procédés associés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3250563T3 true DK3250563T3 (da) | 2022-01-31 |
Family
ID=55305123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16703250.7T DK3250563T3 (da) | 2015-01-30 | 2016-01-29 | Substituerede triazoler og fremgangsmåder, der vedrører disse |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9718789B2 (fr) |
| EP (1) | EP3250563B1 (fr) |
| JP (1) | JP6728198B2 (fr) |
| KR (1) | KR102575601B1 (fr) |
| CN (1) | CN107406420B (fr) |
| AU (1) | AU2016211292B2 (fr) |
| BR (1) | BR112017016488A2 (fr) |
| CA (1) | CA2975474C (fr) |
| CY (1) | CY1125082T1 (fr) |
| DK (1) | DK3250563T3 (fr) |
| ES (1) | ES2905878T3 (fr) |
| HR (1) | HRP20220327T1 (fr) |
| HU (1) | HUE058156T2 (fr) |
| IL (1) | IL253705B (fr) |
| LT (1) | LT3250563T (fr) |
| MX (1) | MX2017009824A (fr) |
| PL (1) | PL3250563T3 (fr) |
| PT (1) | PT3250563T (fr) |
| RS (1) | RS62862B1 (fr) |
| RU (1) | RU2718049C2 (fr) |
| SI (1) | SI3250563T1 (fr) |
| WO (1) | WO2016123533A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| SG11201701998XA (en) | 2014-09-15 | 2017-04-27 | Actelion Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
| JP6728198B2 (ja) | 2015-01-30 | 2020-07-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 置換トリアゾールおよびそれに関する方法 |
| PT3554490T (pt) | 2016-12-16 | 2022-03-17 | Idorsia Pharmaceuticals Ltd | Combinação farmacêutica compreendendo um bloqueador de canais de cálcio de tipo t |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| TW513301B (en) * | 1999-03-01 | 2002-12-11 | Novartis Ag | Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders |
| US7319110B2 (en) * | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
| EP1829867A1 (fr) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Composés d'imidazole ayant une acitivité pharmaceutique vis-à-vis le recepteur sigma |
| EP1921071A1 (fr) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3-Triazoles en tant qu'inhibiteurs du récepteur sigma |
| EP1921073A1 (fr) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazoles en tant qu'inhibiteurs du récepteur sigma |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| EP2752411A1 (fr) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de 1,2,3-triazole-4-amine pour le traitement de maladies et de troubles associés au récepteur sigma |
| JP6728198B2 (ja) | 2015-01-30 | 2020-07-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 置換トリアゾールおよびそれに関する方法 |
-
2016
- 2016-01-29 JP JP2017540175A patent/JP6728198B2/ja active Active
- 2016-01-29 AU AU2016211292A patent/AU2016211292B2/en active Active
- 2016-01-29 CA CA2975474A patent/CA2975474C/fr active Active
- 2016-01-29 RU RU2017130474A patent/RU2718049C2/ru active
- 2016-01-29 HU HUE16703250A patent/HUE058156T2/hu unknown
- 2016-01-29 WO PCT/US2016/015740 patent/WO2016123533A1/fr active Application Filing
- 2016-01-29 LT LTEPPCT/US2016/015740T patent/LT3250563T/lt unknown
- 2016-01-29 US US15/010,925 patent/US9718789B2/en active Active
- 2016-01-29 CN CN201680016876.2A patent/CN107406420B/zh active Active
- 2016-01-29 ES ES16703250T patent/ES2905878T3/es active Active
- 2016-01-29 EP EP16703250.7A patent/EP3250563B1/fr active Active
- 2016-01-29 PT PT167032507T patent/PT3250563T/pt unknown
- 2016-01-29 HR HRP20220327TT patent/HRP20220327T1/hr unknown
- 2016-01-29 PL PL16703250T patent/PL3250563T3/pl unknown
- 2016-01-29 MX MX2017009824A patent/MX2017009824A/es unknown
- 2016-01-29 RS RS20220093A patent/RS62862B1/sr unknown
- 2016-01-29 KR KR1020177023771A patent/KR102575601B1/ko active IP Right Grant
- 2016-01-29 BR BR112017016488A patent/BR112017016488A2/pt not_active Application Discontinuation
- 2016-01-29 DK DK16703250.7T patent/DK3250563T3/da active
- 2016-01-29 SI SI201631489T patent/SI3250563T1/sl unknown
-
2017
- 2017-06-22 US US15/630,225 patent/US10138214B2/en active Active
- 2017-07-27 IL IL253705A patent/IL253705B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,025 patent/US10738017B2/en active Active
-
2020
- 2020-06-04 US US16/892,718 patent/US11021449B2/en active Active
-
2022
- 2022-03-16 CY CY20221100210T patent/CY1125082T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3307707T3 (da) | Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3215601T3 (da) | Fremgangsmåder til transduktion og celleforarbejdning | |
| DK3310371T3 (da) | Glucagon og GLP-1-Co-agonistforbindelser | |
| DK3201351T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
| DK3316909T5 (da) | Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3161124T3 (da) | Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3212218T3 (da) | GIP-agonistforbindelser og fremgangsmåder | |
| DK3368663T3 (da) | Virusfri cellelinjer og fremgangsmåder til opnåelse deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3250563T3 (da) | Substituerede triazoler og fremgangsmåder, der vedrører disse | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3265123T5 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3130669T3 (da) | Ny bakteriophag og sammensætning omfattende denne | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf |